edison tv
Metals & Mining
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: OpGen
Edison Investment Research has terminated coverage on OpGen (OPGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
OpGen — 5 videos in collection
OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.
• Tell us about OpGen’s focus on and approach to antimicrobial resistance.
• Please describe your licensing strategy for Ares Genetics.
• How large do you anticipate the unmet need in the genomic sequencing market to be?
• Which milestones should investors focus on in the coming year?
Get access to the very latest content matched to your personal investment style.